Stockbabie NewsFatherMarketNewsMarket Intelligence
MARKETS
Wire · Markets
Markets

Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1

Oct 27, 2026 · 03:34 AM ET· updated 1h ago

Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1First EU approval of Enhertu in

Share
Why It Matters

Daiichi Sankyo's cancer drug Enhertu got approval in Europe. A big study showed it cut recurrence risk by more than half compared to the older treatment.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
AZN171.51
-0.55 (-0.32%)
DSNKY17.89
+0.05 (+0.28%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.